A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small lung cancer (NSCLC)

被引：0
|
作者：
Camidge, D. R.
Ballas, M. S.
Dubey, S.
Haigentz, M.
Rosen, P. J.
Spicer, J. F.
West, H. J.
Shah, G. D.
Youssoufian, H.
Mita, A. C.
机构：
[1] Univ Colorado Denver, Aurora, CO USA
[2] NYU, Ctr Canc, New York, NY USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Montefiore Med Ctr, Bronx, NY 10467 USA
[5] Tower Canc Res Fdn, Beverly Hills, CA USA
[6] Guys Hosp, Div Canc Studies, Kings Coll London, London SE1 9RT, England
[7] Swedish Canc Inst, Seattle, WA USA
[8] ImClone Syst, New York, NY USA
[9] ImClone Syst, Branchburg, NJ USA
[10] Univ Texas Hlth Sci Ctr San Antonio, Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7588
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7588
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Evaluation of clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open-label, first-line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS)
    Wu, Y.
    Mok, T.
    Chu, D.
    Han, B.
    Liu, X.
    Zhang, L.
    Zhou, C.
    Rukazenkov, Y.
    Duffield, E.
    Fukuoka, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS)
    Fukuoka, M.
    Wu, Y.
    Thongprasert, S.
    Yang, C.
    Chu, D.
    Saijo, N.
    Watkins, C.
    Duffield, E.
    Armour, A.
    Mok, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer
    Zhefeng Liu
    Zhimin Wei
    Yi Hu
    Feng Gao
    Lu Hao
    Ping Fang
    Shengjie Sun
    Jinyu Li
    Shunchang Jiao
    Medical Oncology, 2015, 32
  • [44] Overall Survival and Progression Free Survival Results for a Randomized Phase 2 Trial of Ipilimumab (IPI) and Paclitaxel/Carboplatin (P/C) in First-Line Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
    Lynch, T. J.
    Neal, J.
    Bondarenko, I.
    Luft, A.
    Serwatowski, P.
    Barlesi, F.
    Chacko, R.
    Sebastian, M.
    Cuillerot, J.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S515 - S515
  • [45] A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer
    Liu, Zhefeng
    Wei, Zhimin
    Hu, Yi
    Gao, Feng
    Hao, Lu
    Fang, Ping
    Sun, Shengjie
    Li, Jinyu
    Jiao, Shunchang
    MEDICAL ONCOLOGY, 2015, 32 (08)
  • [46] BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab plus Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer
    Hainsworth, John D.
    Fang, Liang
    Huang, Jane E.
    Karlin, David
    Russell, Kenneth
    Faoro, Leonardo
    Azzoli, Christopher
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (01) : 109 - 114
  • [47] Randomized phase II study of human anti-platelet-derived growth factor receptor alpha (PDGFR(alpha)) monoclonal antibody (IMC-3G3) with paclitaxel/carboplatin (P/C) or P/C alone in first-line treatment of state IIIb/IV non-small cell lung cancer (NSCLC)
    Gerber, D. E.
    Brekken, R. A.
    Hoang, T.
    Youssoufian, H.
    Rowinsky, E. K.
    Loizos, N.
    Shah, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] Analyses of Japanese patients recruited in IPASS, a phase III, randomized, open-label, first-line study of gefitinib vs carboplatin/paclitaxel in selected pts with advanced non-small-cell lung cancer
    Ichinose, Yukito
    Nishiwaki, Yutaka
    Ohe, Yuichiro
    Yamamoto, Nobuyuki
    Negoro, Shunichi
    Duffield, Emma
    Jiang Haiyi
    Saijo, Nagahiro
    Mok, Tony
    Fukuoka, Masahiro
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S443 - S443
  • [49] A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer
    Cejalvo, Juan-Miguel
    Jacob, Wolfgang
    Kanonnikoff, Tania Fleitas
    Felip, Enriqueta
    Navarro Mendivil, Alejandro
    Martinez Garcia, Maria
    Garcia, Alvaro Taus
    Leighl, Natasha
    Lassen, Ulrik
    Mau-Soerensen, Morten
    Adessi, Celine
    Michielin, Francesca
    James, Ian
    Ceppi, Maurizio
    Hasmann, Max
    Weisser, Martin
    Cervantes, Andres
    ESMO OPEN, 2019, 4 (04)
  • [50] FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Lee, J. S.
    Ignacio, J.
    Yu, C.
    Zhou, C.
    Wu, Y.
    Chen, Y.
    Zhang, L.
    Jin, K.
    Johnston, M.
    Mok, T. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345